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Abstract
The inheritance of DNA methylation patterns is a popular theory to explain the influence of parental genetic and
environmental factors on the phenotype of their offspring but few studies have examined this relationship in humans. Using
120 paired maternal-umbilical cord blood samples randomly selected from a prospective birth cohort in Bangladesh, we
quantified DNA methylation by pyrosequencing seven CpG positions in the promoter region of p16, four CpG positions in
the promoter region of p53, LINE-1 and Alu. Positive correlations were observed between maternal and umbilical cord blood
at p16, LINE-1, and Alu but not p53. Multiple linear regression models observed a significant association between maternal
and umbilical cord blood at LINE-1 and Alu (LINE-1: b=0.63, p,0.0001; Alu: b=0.28, p=0.009). After adjusting for multiple
comparisons, maternal methylation of p16 at position 4 significantly predicted methylation at the same position in umbilical
cord blood (b=0.43, p=,0.0001). These models explained 48%, 5% and 16% of the observed variability in umbilical cord
%5mC for LINE-1, Alu and p16 at position 4, respectively. These results suggest that DNA methylation in maternal blood was
correlated with her offspring at LINE-1, Alu, and p16 but not p53. Additional studies are needed to confirm whether these
observed associations were due to the inheritance of epigenetic events or the shared environment between mother and
fetus. Future studies should also use a multi-generational family-based design that would quantify both maternal and
paternal contributions to DNA methylation in offspring across more than one generation.
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Introduction
DNA methylation is an epigenetic modification that involves the
covalent addition of a methyl group to a cytosine at the 59-position
of a CpG dinucleotide [1]. CpG dinucleotides are clustered in the
promoter regions of genes [2] and in highly repeated elements
such as long interspersed nucleotide elements (LINE-1) and Alu
[3,4]. There are approximately 1.4 million Alu repeated elements
and a half million LINE-1 repeated elements in the human
genome. The CpG dinucleotides in these repeated elements are
typically heavily methylated in order to silence their expression.
They are also transposable, that is, expression can lead to insertion
into other genomic regions which can result in gene silencing
[5,6]. These interspersed repetitive elements may serve as
surrogate markers for global DNA methylation [7]. CpG rich
regions are also found in approximately half of the gene promoter
regions. Typical CpG islands are not methylated which allows for
normal gene transcription [8]. In many complex diseases including
cancer, atherosclerosis, Alzheimer’s disease, and psychiatric
disorders it is common to observe global DNA hypomethylation,
as well as, gene specific hypermethylation [9,10]. Global DNA
hypomethylation is associated with genomic instability and gene
specific hypermethylation is associated with gene silencing [11,12].
In early embryogenesis, there are two waves of demethylation
which are completed by the morula stage[13–15]. These erasures
are quickly followed by an increase in de novo methylation which
allows for the acquisition of imprinted genes and epigenetic
programming associated with tissue differentiation [13–15]. It is
believed that this re-programming of epigenetic marks during
embryogenesis ensures that gametes acquire the appropriate sex-
specific epigenetic states and that epimutations acquired by the
adult germ cells are removed [16].
The heritability of epigenetic marks between generations is
frequently used to explain the etiology of traits and diseases that do
not follow Mendelian inheritance patterns. Transgenerational
inheritance of DNA methylation has been described in plants,
yeast, Drosophila, and mouse models for both transgenes and
endogenous alleles [17–20]. However, the inheritance of DNA
methylation in humans has only been evaluated in families with a
history of cancer. Studies of hereditary nonpolyposis colorectal
cancer have observed hypermethylation of DNA mismatch repair
genes (MSH2 and MLH1) in the proband and their affected
children [21–24]. In families with a history of testicular cancer,
researchers have observed strong gender-specific LINE-1 methyl-
ation patterns between parents and offspring, particularly between
affected father-affected son pairs [25].
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13730To better understand the relationship of epigenetic patterns in
parent-offspring pairs, we evaluated DNA methylation patterns in
120 paired maternal-child samples collected in a prospective
reproductive health study recruited in Bangladesh. This observa-
tional study used pyrosequencing to quantify DNA methylation in
peripheral leukocytes at two tumor suppressor genes (p16 and p53)
and two repetitive elements (LINE-1 and Alu). The tumor
suppressor genes were selected because both p16 and p53 have
well characterized CpG positions in their promoter regions.
Furthermore, p16 expression is well known to be regulated via
DNA methylation [26].
Results
Average blood DNA methylation levels, expressed at %5mC
(percentage of cytosines that are methylated over unmethylated
cytosines at a given CpG position), are presented in Table 1. On
average, DNA methylation for LINE-1 was 80.1 (SD=2.1) and
80.6 (SD=1.9) and Alu was 25.2 (SD=0.7) and 25.0 (SD=0.8) in
maternal and umbilical cord samples, respectively. Paired t-tests
detected very slight differences in %5mC between maternal and
umbilical cord blood with umbilical cord blood containing, on
average, 0.5% (p=0.007) more methylated cytosines at LINE-1
compared to maternal blood. Whereas, maternal blood contained
on average 0.25% (p=0.006) more methylated cytosines at Alu
compared to umbilical cord blood. Gender specific paired t-tests
observed a slight difference at LINE-1 and Alu between mother-
daughter pairs but not between mother-son pairs. On average,
daughters had 0.4% less DNA methylation at LINE-1 (M=20.43,
SD=1.48, p=0.04), and 0.3% more DNA methylation at Alu
(M=0.32, SD=0.76, p=0.003) compared to their mothers.
DNA methylation was also measured at 7 and 4 CpG
dinucleotides within the promoter regions of p16 and p53,
respectively. DNA methylation was very low at all CpG
dinucleotides in both p16 and p53 (Table 1). This was expected
because the promoter regions of these genes have low levels of
methylation in healthy individuals. Paired t-tests detected very
slight differences in %5mC at position 7 in p16 with umbilical cord
blood containing, on average, 0.5% (p=0.02) more methylated
cytosines at this CpG dinucleotide compared to maternal blood.
Gender specific paired t-tests only observed a difference in DNA
methylation at position 7 in p16 in maternal-daughter pairs with
daughters having 0.9% more methylation compared to their
mothers (M=0.9, SD=2.5, p=0.02). No difference in DNA
methylation at any of the 7 CpG dinucleotides in p16 was observed
in mother-son pairs.
Paired t-tests detected a very slight difference in %5mC at
position 3 in p53 with umbilical cord blood containing, on average,
0.2% (p=0.008) more methylated cytosines compared to maternal
blood. Gender specific paired t-tests observed a difference in DNA
methylation at position 2 and position 3 in p53 in maternal-
daughter pairs with daughters having 0.8% and 0.5% more
methylation at position 2 and 3 compared to their mother (p53
position 2: M=0.77; SD=2.61, p=0.05; p53 position 3 M=0.48;
SD=1.28, p=0.01). No differences in DNA methylation at any of
the 4 CpG dinucleotides in p53 was observed in maternal-son
pairs. These results suggested that there were gender-specific
differences in DNA methylation in p53 and daughters had slightly
less DNA methylation at LINE-1 and slightly more DNA
methylation at Alu, p16 and p53 compared to their mothers.
Significant correlations were observed between DNA methyl-
ation in maternal-umbilical cord pairs (Table 2). Positive
correlations were observed between maternal-umbilical cord pairs
at LINE-1 (ss=0.63, p,0.0001), Alu (ss=0.31, p,0.0001), in p16
(p16 position 1: ss=0.38, p,0.0001; p16 position 2: ss=0.49,
p,0.0001; p16 position 3: ss=0.35, p=0.0004; p16 position 4:
ss=0.54, p,0.0001; p16 position 5: ss=0.17, p=0.09; p16
position 6: ss=0.46, p,0.0001; p16 position 7: ss=0.41,
p,0.0001;). A positive correlation was observed at position 4 in
p53 but not at any of the other 3 positions tested (p53 position 1:
ss=0.13, p=0.24; p53 position 2: ss=0.13, p=0.22; p53
position 3: ss=20.07, p=0.54; p53 position 4: ss=0.22,
p=0.04). It is interesting to note that LINE-1 was positively
correlated with p16 and p53, but negatively correlated with Alu
despite the fact that they are both used as surrogate markers of
global methylation status. To test whether the observed regression
results would be similar in unrelated individuals, the samples were
randomly re-assigned so that the paired samples were no longer
related. In the randomly re-assigned data, there was no correlation
between maternal-umbilical cord samples at LINE-1, Alu, p16 or
p53 (data not shown).
Multiple linear regression models evaluated whether the %5mC
in maternal blood significantly predicted %5mC in umbilical cord
blood (Figure 1 A–M). These models adjusted for infant sex,
mother’s age, and arsenic exposure in the mother’s drinking water
during pregnancy. Maternal methylation of LINE-1 and Alu
significantly predicted umbilical cord %5mC in LINE-1 and Alu,
respectively (Figure 1A and 1B: b=0.63, p,0.0001; b=0.28,
p=0.009). These models explained 48% and 5% of the observed
variability in umbilical cord DNA methylation at LINE-1 and Alu.
At 6 of the 7 CpG positions screened in p16, the %5mC in
maternal blood significantly predicted the %5mC in the
corresponding CpG positions in the umbilical cord blood
(Figure 1C p16 position 1: b=0.19, p=0.003; Figure 1D p16
position 2: b=0.27, p=0.0005; Figure 1F p16 position 4: b=0.43,
p,0.0001; Figure 1H p16 position 6: b=0.33, p=0.003; Figure 1I
p16 position 7: b=0.17, p=0.001). These models explained 3%,
9%, 16%, 7%, and 7% of the observed variability in umbilical
cord DNA methylation at p16 position 1, 2, 4, 6, and 7,
respectively. Using a more stringent a=0.007 to account for the
Table 1. General descriptive statistics for paired maternal-
cord blood samples included in the analysis.
Maternal
Blood
Cord
Blood T-test
n Mean SD Mean SD Dif. p-value
Alu 103 25.2 0.71 24.96 0.78 0.25 0.007
LINE-1 98 80.11 2.10 80.58 1.92 20.46 0.006
p16
pos1 100 2.61 1.65 2.41 1.43 0.20 0.31
pos2 100 3.03 1.66 2.83 1.29 0.20 0.25
pos3 100 1.35 0.66 1.38 0.76 20.03 0.75
pos4 100 2.18 1.02 2.05 0.98 0.13 0.24
pos5 100 2.16 0.70 2.07 0.91 0.09 0.46
pos6 100 1.23 0.70 1.30 0.78 20.07 0.41
pos7 100 2.90 2.17 2.38 1.13 0.52 0.02
p53
pos1 87 2.80 1.76 2.55 0.90 0.26 0.23
pos2 87 7.92 2.52 7.39 2.29 0.54 0.13
pos3 87 2.77 0.97 2.41 0.71 0.36 0.008
pos4 87 3.83 1.65 3.68 1.28 0.15 0.48
doi:10.1371/journal.pone.0013730.t001
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PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13730Figure 1. Partial regression plots including the effect estimate and p-value from multiple regression analysis that test the
association between %5mC in umbilical cord and maternal blood at LINE-1. (Panel A), Alu (Panel B), seven CpG positions in the p16
promoter (Panels C–I), and four CpG positions in the p53 promoter (Panels J–M).
doi:10.1371/journal.pone.0013730.g001
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CpG positions within the promoter region of p16, only the %5mC
at position 4 in maternal blood remained highly significant.
Maternal methylation of p53 was not a significant predictor of
umbilical cord %5mC at any of the 4 CpG dinucleotides assayed
(Figures 1J–M).
Discussion
Unlike DNA sequence mutations, the inheritance patterns of
epigenetic events in humans are poorly understood. This
epidemiological study observed that DNA methylation levels in
LINE-1, Alu, and p16 appeared to be positively associated in
healthy mother-infant pairs. However, evaluating changes in
epigenetic patterns from one generation to the next must be
interpreted cautiously because such marks are both cell specific
and malleable. Many factors have been shown to influence DNA
methylation including gender [27], aging [28,29], environmental
factors [30,31], and heterogeneous peripheral blood leukocyte
populations [32,33]. In addition, the timing of the measurement,
cell type, external environment and the function of the mark (i.e.
gene expression regulation which changes with life stage) could
influence the observed pattern. Aside from imprinted genes, the
evidence that some epigenetic marks are inherited across
generations comes largely from animal models [34]. For example,
in mice the transgenerational epigenetic inheritance of the agouti
viable yellow (A
vy) allele and the axin-fused (Axin
Fu) allele, which both
include a IAP retrotransposon in their sequence, has been
demonstrated [35,36].
Few studies have investigated transgenerational patterns of
epigenetic marks in humans and these have mostly been limited to
families with a history of disease. For instance, in families with a
history of hereditary nonpolyposis colorectal cancer, there is
evidence of heritable germline inheritance of hypermethylated
promoter region in DNA mismatch repair genes including mutL
homolog 1 (MLH1) and mutL homolog 2 (MLH2) alleles that suggests
individuals who inherited these epimutations have a predisposition
to this particular type of cancer [22,23,37]. Another study in
families with a history of testicular cancer reported that global
methylation at LINE-1 in peripheral blood of offspring were
significantly positively correlated with parental levels, particularly
between mother-daughter (r=0.48, p-value=,0.001), father-
daughter (r=0.31, p-value=0.02), and affected father-affected
son pairs (r=0.49, p-value=0.03) [25]. Two additional studies
also suggest that global methylation patterns may be inherited.
Hillemacher et al, who compared DNA methylation in 73 fathers,
69 mothers and 156 grown offspring, reported an association
between offspring’s and paternal DNA methylation if both had
never smoked (r=0.41, b=0.68, p=0.02) [38]. Sandovici et al
conducted a study of three-generation families and reported
familial clustering of high methylation at Alu amongst individuals
who came from families in which one member exhibited abnormal
patterns of methylated regions of the IGF2/H19 or IGF2R loci
[39].
In this study, the strongest association in maternal-infant pairs
was with LINE-1. Furthermore, the strength of the correlation
observed (r=0.48) was similar that observed in the families with a
history of testicular cancer [25]. Although it is interesting to note
that human LINE-1 elements include an intracisternal A particle
(IAP) retrotransposon in their sequence that is very similar to the
IAP which determines epigenetic inheritance in the A
vy and Axin
fu
animal models [40]. This could explain the strong parent-offspring
associations observed by both Mirabello et al [25] and this study.
However, it should be noted that the association at LINE-1 reflects
an average methylation across over 500,000 loci across the
genome and is not specific to correlations between any given loci.
Therefore, it is possible that the associations observed in this study
reflect a more global methylation capacity which could be due to
inherited methyltransferase genes.
We also observed that LINE-1 and Alu methylation levels were
inversely associated with each other. However, studies that have
used DNA from tumor samples have shown that the LINE-1 and
Alu methylation were correlated with each other [41,42]. No
significant correlations have been reported, to the best of our
knowledge, between LINE-1 and Alu methylation levels in non-
malignant tissue samples such as blood leukocytes [43,44]. The
finding of a negative correlation between LINE-1 and Alu conflicts
with the hypothesis of a direct role of general methyltransferase
activities in determining the observed mother-child correlations,
and suggest more complex, position-specific mechanisms. There is
growing evidence that Alu and LINE-1 have distinct functional
roles that may account for different and even inverse methylation
patterns within the same subjects as was observed in this study
[45]. For instance, there is recent evidence showing that Alu and
LINE-1 undergo opposite DNA methylation changes as individuals
age [31,46]. Therefore, our results provide further indirect
evidence that LINE-1 and Alu may respond differently or have
distinct functional roles in non-malignant tissues.
While it is possible that the observed correlation between
maternal-infant DNA methylation patterns is a result of maternal
contamination of umbilical cord blood due to leakage between
maternal-fetal circulation during pregnancy and/or partition [47],
this explanation is unlikely because we did not observe any
association between maternal and umbilical cord blood DNA
methylation with p53. While our multiple linear regression models
adjusted for maternal age and the sex of the infant, it is also
possible that shared environmental factors between the mother
and fetus explain the observed DNA methylation patterns. This
population was recruited in Bangladesh as part of a reproductive
health study examining the role of arsenic exposure on
reproductive health outcomes. While our analysis controlled for
arsenic concentration in the mother’s drinking water during
pregnancy, the effects of arsenic exposure in mothers and fetus
cannot be teased apart for obvious reasons. Arsenic is a suspected
epigenetic toxicant [48,49]. Nor did we control for dietary factors
that can influence DNA methylation such as folate and
homocysteine [50,51], but again any exposure to a mother will
by default occur in the fetus. Also, gene expression is regulated at
least in part by DNA methylation. If particular genes (or
retrotransposons) need to be expressed in order to preserve cell
function at specific life stages, this constitutional need will tend to
increase the correlation between subjects.
Another limitation of this study is that we were unable to adjust
for the distribution of peripheral blood leukocyte populations in
our whole blood samples or the timing of the blood sample
collection from the umbilical cord. Also, paternal DNA from blood
leucocytes was not collect which prevented us from examining the
correlation between paternal DNA methylation and their
offspring. Ideally, a case-parent trio design would be employed
to examine the degree of DNA methylation between both parents
and their offspring.
In conclusion, the results of this study suggest that LINE-1, Alu
and p16 DNA methylation in maternal blood collected during
pregnancy predicts the DNA methylation patterns in the cord
blood of her newborn. We did not find correlation for p53
methylation. Overall our results are consistent with the hypothesis
that some, but not all, DNA methylation marks may be heritable;
however, it is also possible that these associations are due to the
Maternal-Cord DNA Methylation
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constitutional methylation patterns that are necessary for cell
function. Multi-generational family-based studies are needed to
determine the extent to which LINE-1, Alu and p16 are heritable.
Materials and Methods
Subject Selection and Recruitment
This study was approved by the Human Research Committees
at the Harvard School of Public Health and Dhaka Community
Hospital (DCH). All volunteers provided written consent before
participating in the study.
We used 120 paired maternal-umbilical cord blood samples
collected as part of an ongoing prospective birth cohort that is
investigating the effects of prenatal arsenic exposure on reproduc-
tive health outcomes. This study is recruiting pregnant women
residing in the Sirajdikhan and Pabna Upazilas of Bangladesh
through active surveillance in the districts. Women were eligible
for the study if they were 18 years of age or older, had an
ultrasound-confirmed singleton pregnancy of less than 28 weeks’
gestation, used a tubewell as their primary drinking water source
when they conceived, planned to live at their current residence for
the duration of the pregnancy, planned to continue prenatal health
care with Sirajdikhan Community Clinic a rural health care clinic
operated by DCH, and agreed to deliver at DCH or at home with
a DCH-trained midwife. All participants were provided with a free
supply of prenatal vitamins that was refilled monthly when field
staff visited each participant in their home. Informed consent was
obtained from all participants before enrollment.
Exposure Assessment
Water samples were collected from each participant’s tubewell
at the time of enrollment. Tubewells were purged by pumping the
well for several minutes before 50 mls of water was collected in an
acid-washed polypropylene tube (BD Falcon, BD Bioscience,
Bedford, MA). Samples were preserved with Reagent Grade
HNO3 (Merck, Germany) to a pH,2 and kept at room
temperature until analysis. Arsenic concentrations were quantified
by inductively coupled plasma-mass spectrometry using US EPA
method 200.8 (Environmental Laboratory Services, North Syr-
acuse, New York). Analysis was validated using PlasmaCAL multi-
element QC standard #1 solution (SCP Science, Canada). The
average percent recovery for InAs was 10267%. The limit of
detection (LOD) for this method is 1 mg As/L. Samples below the
LOD were assigned a value of 0.5 mg As/L.
Peripheral Blood Collection and DNA extraction
A peripheral whole blood sample was collected from the
participant when they enrolled in the study and umbilical cord
blood was collected at the time of delivery. DNA was extracted
from 4 mls of whole blood using Puregene DNA isolation kits
(Qiagen/Gentra Systems, Minneapolis, MN) following manufac-
turers instructions. Extracted DNA was stored at 220uC until
further analysis.
DNA Methylation
DNA methylation analyses were performed in duplicate on
bisulfite-treated DNA using highly-quantitative analysis based on
PCR-Pyrosequencing where 0.5 mg DNA (concentration 25 ng/
ml) was treated using the EZ-96 DNA Methylation-Gold
TM Kit
(Zymo Research, Orange, CA, USA) according to the manufac-
turer’s protocol. Final elution was performed with 30 ml M-Elution
Buffer.
In brief, DNA was amplified using bisulfite-PCR where a biotin-
labeled primer was used to purify the final PCR product by
Streptavidin Sepharose (Amersham Biosciences, Uppsala, Sweden)
and the Pyrosequencing Vacuum Prep Tool (Pyrosequencing,
Figure 2. Examples of pyrograms. A) LINE-1,B )Alu,C )p16, and D) p53.
doi:10.1371/journal.pone.0013730.g002
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tions. Then the PCR product underwent pyrosequencing using the
PyroMark
TMQ96 MD Pyrosequencing System (Pyrosequencing,
Inc., Westborough, MA) as previously described [52] using
0.3 mM sequencing primer. Examples of the pyrograms for each
sequence are presented in Figure 2.
The degree of methylation was expressed for each DNA locus as
the percentage methylated cytosine over the sum of methylated
and unmethylated cytosine. Non-CpG cytosine residues were used
as built-in controls to verify bisulfite conversion. Each marker was
tested in two replicates and their average was used in the statistical
analysis.
To estimate global DNA methylation content we performed
DNA methylation analyses of Alu and LINE-1 repeated sequences,
which allow for the amplification of a representative pool of
repetitive elements, as previously described [30]. p16 DNA
methylation was measured using primers and conditions devel-
oped by Shaw et al [53]. We developed the assay for p53
methylation by locating the p53 promoter, using the Genomatix
Software (Genomatix Software Inc, Ann Arbor, MI). Table 3
shows the localization of gene promoters, regions amplified and
CpGs analysed for p16 and p53.
A5 0mL PCR was carried out in 25 mL GoTaq Green Master
mix (Promega, Madison, WI, USA), 10 pmol forward primer,
10 pmol reverse primer, 50 ng bisulfite-treated genomic DNA,
and water. PCR cycling conditions were 95uC for 60s, 57uC for
60 s and 72uC for 60 s for 50 cycles. PCR products were purified
and sequenced by pyrosequencing as previously described [54]
using 0.3 mM sequencing primer. Primers for Alu, LINE-1, p16 and
p53 assay are shown in Table 4.
In total, 120 paired maternal-umbilical cord blood
samples underwent DNA methylation analysis. The %5mC
was measured in LINE-1, Alu, seven specific positions in p16,
and four specific positions in p53. The success of pyrosequenc-
ing ranged from 100% for Alu in maternal blood to 79% for p53
in umbilical cord blood. For those assays that were unsuccessful,
the paired maternal-umbilical cord sample was excluded from
analysis.
Table 3. Localization of gene promoters and regions amplified and of the CpG dinucleotide positions at which DNA methylation
was quantified.
Gene Chromosome Promoter Amplicon CpGs
Start End Start End
p16 9 21964701 21965538 21965321 21965395 21965350 (position 1)
21965355 (position 2)
21965357 (position 3)
21965361 (position 4)
21965365 (position 5)
21965368 (position 6)
21965374 (position 7)
p53 17 7531143 7531743 7531409 7531628 7531486 (position 1)
7531473 (position 2)
7531469 (position 3)
7531458 (position 4)
doi:10.1371/journal.pone.0013730.t003
Table 4. Primers used for DNA methylation analysis.
ID Forward Primer Reverse Primer Sequencing Primer Sequence analyzed
a
(59 to 39)( 5 9 to 39)( 5 9 to 39)
Global methylation
analysis
Alu Biotin-TTTTTATTA-
AAAATATAAAAATT
CCCAAACTAA-
AATACAATAA
AATAACTAAA-
ATTACAAAC
G/AC/TG/AC/-
TG/ACCACCA
LINE–1 TTTTGAGTTAGG-
TGTGGGATATA
Biotin-AAAATCAA-
AAAATTCCCTTTC
AGTTAGGTGTG-
GGATATAGT
TTC/TGTGG-
TGC/TGTC/TG
Gene-specific
methylation analysis
p16 AGGGGTTGGTTGG-
TTATTAG
Biotin - CTACCTACTC-
TCCCCCTCTC
GGTTGGTTAT-
TAGAGGGT
GGGGC/TGGATC/TGC/TGT-
GC/TGTTC/TGGC/TGGTTGC/TG
p53 Biotin -TTAGGAGTTTAT-
TTAATTTAGGGAAG
TATCCAACTTTATA-
CCAAAAACCTC
TCCAAAAAACAA-
ATAACTACTAAACTC
CG/AAAAACACTTTACG/ATTCG/AA-
ACTAAAAACG/ATACTTT
aNucleotides at which DNA methylation was measured are underlined.
doi:10.1371/journal.pone.0013730.t004
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Descriptive statistics were calculated for the maternal and cord
blood samples. Differences between umbilical cord blood and
maternal blood %5mC were evaluated using Wilcoxon-Rank Sum
Tests. Spearman correlations coefficients that adjusted for
drinking water arsenic exposure (and between batches using a
dummy variable for LINE-1 and Alu) were calculated to evaluate
the association between %5mC in umbilical cord blood and
maternal blood. Multiple linear regression models were used to
evaluate the relationship between %5mC in umbilical cord blood
(dependent variable) and maternal blood (predictor) for each
marker. All regression models included drinking water arsenic
exposure, infant sex and maternal age. The residuals from all
regression models were evaluated for normalcy. Bonferroni
correction was used to set the type I error rate at a=0.05/
7=0.007 for p16 and a=0.05/4=0.01 for p53. This is a
conservative approach that should reduce the potential for false
positives associated with quantifying CpG methylation at 7
positions within p16 and 4 positions within p53. All analyses were
performed using SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA).
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